Evaxion Biotech (EVAX) Revenue & Revenue Breakdown
Evaxion Biotech Revenue Highlights
Latest Revenue (Y)
$73.11K
Latest Revenue (Q)
$50.88K
Evaxion Biotech Revenue by Period
Evaxion Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $73.11K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Evaxion Biotech generated $73.11K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Evaxion Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $50.88K | -30.87% |
| 2023-12-31 | $73.60K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-11-14 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | - |
Evaxion Biotech generated $50.88K in revenue during Q1 2024, up -30.87% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Evaxion Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| BDRX | Biodexa Pharmaceuticals | $381.00K | $41.50K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| EVAX | Evaxion Biotech | $73.11K | $50.88K |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| CGEM | Cullinan Oncology | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| ZURA | Zura Bio | - | - |
| REVB | Revelation Biosciences | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| ZVSA | ZyVersa Therapeutics | - | - |
| ALLR | Allarity Therapeutics | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| LABP | Landos Biopharma | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
EVAX Revenue FAQ
What is Evaxion Biotech’s yearly revenue?
Evaxion Biotech's yearly revenue for 2023 was $73.11K, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. EVAX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Evaxion Biotech’s quarterly revenue?
Evaxion Biotech's quarterly revenue for Q1 2024 was $50.88K, a -30.87% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $73.6K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). EVAX's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Evaxion Biotech’s revenue growth rate?
Evaxion Biotech's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.